Clinical Trial Update: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial in borderline resectable or locally advanced unresectable pancreatic cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Pancreatic Cancer, Pancreatic Carcinoma Non-resectable | Phase 3 | Status: TERMINATED